Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy
American Society of Clinical Oncology Educational Book · 2024
DOI: 10.1200/edbk_433330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024. Verfasst von Ari J Rosenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immunotherapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs). Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway with some promising early results. Beyond immune checkpoint inhibition, novel immunotherapeutic strategies including therapeutic vaccines ranging from targeting human papillomavirus–specific epitopes to personalized neoantigen vaccines are ongoing with some early efficacy signals and large, randomized trials. Other novel weapons including bispecific antibodies, fusion proteins, and multitargeted kinase inhibitors leverage multiple concurrent targets and modulation of the tumor microenvironment to harness antitumor immunity and inhibition of protumorigenic signaling pathways with emerging promising results. Finally, as with other solid tumors, ADCs remain a promising therapeutic intervention either alone or in combination with immunotherapy for patients with R/M HNSCC. With early enthusiasm across novel therapies in R/M HNSCC, results of larger randomized trials in R/M HNSCC are eagerly awaited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL.
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL.
- University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, FL.
- Fellow in Clinical Oncology, by the Foundation Center for Oncology Control (FCECON), Manaus-Amazonas, Brazil.
- Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Förderung
- NCI NIH HHS
Zitieren
APA
Rosenberg, A. J., Perez, C. A., Guo, W., de Oliveira Novaes, J. M., da Silva Reis, K. F. O., McGarrah, P. W., & Price, K. A. R. (2024). Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_433330
Vancouver
Rosenberg AJ, Perez CA, Guo W, de Oliveira Novaes JM, da Silva Reis KFO, McGarrah PW, et al. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. American Society of Clinical Oncology Educational Book. 2024. doi:10.1200/edbk_433330
BibTeX
@article{Rosenberg2024,
author = {Rosenberg, Ari J and Perez, Cesar A and Guo, Wenji and de Oliveira Novaes, Jose Monteiro and da Silva Reis, Kamilla F Oliveira and McGarrah, Patrick W and Price, Katharine A R},
title = {Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy},
journal = {American Society of Clinical Oncology Educational Book},
year = {2024},
doi = {10.1200/edbk_433330}
}
EUVIMED